SYK - Integra LifeSciences Bails Out Of A Once-Promising Growth Opportunity
- Integra and Smith & Nephew announced a deal wherein Smith & Nephew will acquire Integra's orthopedic extremities business for $240 million in cash.
- Integra's cobbled-together extremities portfolio could never make much headway, squeezed between better-established leaders and aggressive and innovative startups.
- Management would do well to focus future M&A on targets closer to its core specialties in neuro and wound care.
- Integra looks a little undervalued, but it can be difficult for mid-cap med-techs to stand out without double-digit revenue growth.
For further details see:
Integra LifeSciences Bails Out Of A Once-Promising Growth Opportunity